We’re building on our deep expertise and historic legacy in immunology research to explore new disease areas, create a more patient-centric discovery and development process, and offer solutions for more diverse patient populations. Our advanced technologies support a rich pipeline of medicines for some of the most challenging immunological diseases. Research interests include:
Understanding drivers of disease
Increasing understanding of disease through molecular profiling of patient samples, exploring preclinical disease to post-treatment states and using multi-omics, machine learning and artificial intelligence.
Fit for purpose drug discovery
Redesigning drug discovery using molecular profiles that reveal the genetic makeup of disease rather than diagnoses that describe disease.
Increasing probability of success in drug discovery
Developing more humanized preclinical model systems (e.g., CRISPR, iPSC, organoids and disease-on-a-chip) and state-of-the-art immunological, imaging and computational approaches to drive innovation of target identification, validation, benchmarking and prioritization.
Inducing of immune tolerance
Pursuing the biology behind inducing tolerance rather than suppressing pathological immune activity.
Drug delivery platforms
Investing in targeted drug delivery platforms, which are designed to specifically deliver a potent drug to the right cells and/or tissues. These include bispecifics, Antibody-Drug Conjugate platforms, small molecule approaches, RNA therapeutics and in situ cell reprogramming.